查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1422924

2024-2032年系統性紅斑狼瘡藥物市場按藥物類別（抗瘧藥、非類固醇抗發炎藥、細胞毒性及免疫抑制藥物、生物製劑等）、給藥方式及地區

Systemic Lupus Erythematosus Drugs Market by Drug Class (Antimalarials Drugs, Non-Steroidal Anti-Inflammatory Drugs, Cytotoxic and Immunosuppressive Drugs, Biologics, and Others), Mode of Delivery, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3個工作天內

價格

2023年，全球系統性紅斑狼瘡（SLE）藥物市場規模達到27億美元。展望未來， IMARC Group預計到2032年市場規模將達到45億美元，2024-2032年複合年成長率（CAGR）為5.83%患有系統性紅斑狼瘡的患者數量不斷增加、公眾宣傳活動不斷加強以及學名藥的容易獲得是推動市場發展的一些關鍵因素。

系統性紅斑狼瘡 (SLE) 是一種自體免疫疾病，其特徵是多變的臨床表現、多系統發炎 (MIS) 和復發緩解病程 (RRMS)。它影響身體的許多部位，包括皮膚、關節、腎臟和大腦。它通常是由於各種遺傳、環境和荷爾蒙因素引起的。其症狀包括疲勞、關節疼痛和腫脹、頭痛、皮疹、脫髮、貧血、凝血和發燒。系統性紅斑狼瘡由醫療保健提供者透過症狀評估、身體檢查、胸部 X 光檢查、尿液分析和血液檢查來診斷。可以使用治療關節疼痛和僵硬的抗發炎藥物、治療皮疹的類固醇藥膏、減少免疫反應的皮質類固醇以及治療皮膚問題的抗瘧藥來緩解其症狀。它還使用疾病緩解藥物和標靶免疫系統藥物來治療更嚴重的病例。除此之外，還可以使用各種抑制免疫系統活性的免疫抑制藥物來治療。

系統性紅斑狼瘡 (SLE) 藥物市場趨勢：

自體免疫疾病在個體中的盛行率不斷上升，以及患有系統性紅斑狼瘡的患者數量不斷增加，是推動全球系統性紅斑狼瘡藥物需求的主要因素之一。此外，越來越多的研究和診斷機構正在採取措施並進行公眾宣傳活動，以教育個人了解系統性紅斑狼瘡及其可能的治療方法。此外，許多國家的政府和非政府組織（NGO）正在投資各種計畫來開發新療法並確定治療 SLE 的相關藥物標靶。再加上全球用於改善醫療基礎設施和診斷技術的融資不斷增加，正在推動市場成長。除此之外，透過線下和線上零售通路可以輕鬆獲得各種用於緩解與系統性紅斑狼瘡相關的疼痛、發炎和僵硬的學名藥，這有利於市場的成長。它們通常涉及非處方藥(OTC) 和處方非類固醇抗發炎藥(NSAID)，例如阿斯匹靈、布洛芬(美林)、萘普生、塞來昔布(Celebrex)、雙氯芬酸(扶他林)、二氟尼柳(Dolobid) 和吡羅昔康（費爾德內）。此外，羥氯奎藥物使用的增加也促進了市場的成長。除此之外，個人和醫療保健專業人員對系統性紅斑狼瘡早期診斷和治療益處的認知不斷增強，正在影響系統性紅斑狼瘡藥物的整體銷售。

本報告回答的關鍵問題

  • 全球系統性紅斑狼瘡（SLE）藥物市場有多大？
  • 2024-2032年全球系統性紅斑狼瘡（SLE）藥物市場的預期成長率為何？
  • 推動全球系統性紅斑狼瘡（SLE）藥物市場的關鍵因素是什麼？
  • COVID-19 對全球系統性紅斑狼瘡 (SLE) 藥物市場有何影響？
  • 根據藥物類別，全球系統性紅斑狼瘡 (SLE) 藥物市場的細分如何？
  • 根據給藥方式，全球系統性紅斑狼瘡 (SLE) 藥物市場的細分如何？
  • 全球系統性紅斑狼瘡（SLE）藥物市場的主要區域有哪些？
  • 全球系統性紅斑狼瘡 (SLE) 藥物市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球系統性紅斑狼瘡 (SLE) 藥物市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依藥物類別

  • 抗瘧藥
    • 市場走向
    • 關鍵環節
      • 氯奎
      • 羥氯奎
    • 市場預測
  • 非類固醇類抗發炎藥（NSAIDS）
    • 市場走向
    • 市場預測
  • 細胞毒性和免疫抑制藥物
    • 市場走向
    • 關鍵環節
      • 環磷醯胺
      • 甲胺蝶呤
      • 嗎替麥考酚酯
      • 他克莫司
      • 環孢素
    • 市場預測
  • 生物製劑
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：市場區隔：依交付方式

  • 靜脈
    • 市場走向
    • 市場預測
  • 皮下
    • 市場走向
    • 市場預測
  • 口服
    • 市場走向
    • 市場預測

第 8 章：市場區隔：按地區

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 9 章：促進因素、限制與機會

  • 概述
  • 促進要素
  • 限制
  • 機會

第 10 章：價值鏈分析

第 11 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 12 章：價格分析

第13章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AstraZeneca Plc
    • Aurinia Pharmaceuticals Inc.
    • GSK plc
    • ImmuPharma Plc
Product Code: SR112024A6799

Abstract

The global systemic lupus erythematosus (SLE) drugs market size reached US$ 2.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.5 Billion by 2032, exhibiting a growth rate (CAGR) of 5.83% during 2024-2032.The increasing number of patients suffering from SLE, rising public awareness campaigns, and the easy availability of generic drugs represent some of the key factors driving the market.

Systemic lupus erythematosus (SLE) is an autoimmune medical condition characterized by protean clinical manifestations, multisystem inflammation (MIS), and a relapsing and remitting course (RRMS). It affects numerous parts of the body, including the skin, joints, kidneys, and brain. It is generally caused due to various genetic, environmental, and hormonal factors. Its symptoms include fatigue, joint pain and swelling, headache, rashes, hair loss, anemia, blood clotting, and fever. SLE is diagnosed by a healthcare provider using symptom assessments, physical examinations, chest X-rays, urinalysis, and blood tests. Its symptoms can be eased using anti-inflammatory drugs for joint pain and stiffness, steroid creams for rashes, corticosteroids to minimize the immune response, and antimalarial drugs for skin problems. It also uses disease-modifying drugs and targeted immune system agents for more severe cases. Besides this, it is treated using various immunosuppressive drugs that inhibit the activity of the immune system.

Systemic Lupus Erythematosus (SLE) Drugs Market Trends:

The increasing prevalence of autoimmune diseases among individuals and the rising number of patients suffering from SLE represents one of the major factors driving the demand for SLE drugs around the world. Moreover, the rising number of research and diagnostics institutes are undertaking measures and introducing public awareness campaigns to educate individuals about SLE and its possible treatments. In addition, governments and non-governmental organizations (NGOs) of numerous countries are investing in various programs to develop novel therapeutics and identify relevant drug targets for the treatment of SLE. This, coupled with the increasing financing to improve healthcare infrastructure and diagnostic technologies worldwide, is impelling the market growth. Apart from this, the easy availability of various generic drugs for relieving pain, inflammation, and stiffness associated with SLE through offline and online retail channels is favoring the market growth. They generally involve over the counter (OTC) and prescription-based nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen (Motrin), naproxen, celecoxib (Celebrex), diclofenac (Voltaren), diflunisal (Dolobid), and piroxicam (Feldene). Furthermore, the increasing use of Hydroxychloroquine drugs is contributing to the market growth. Besides this, the growing awareness among individuals and healthcare professionals about the benefits of early diagnosis and treatment of SLE is influencing the overall sales of SLE drugs.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global systemic lupus erythematosus (SLE) drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on drug class and mode of delivery.

Drug Class Insights:

Antimalarials Drugs

Chloroquine

Hydroxychloroquine

Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)

Cytotoxic and Immunosuppressive Drugs

Cyclophosphamide

Methotrexate

Mycophenolate Mofetil

Tacrolimus

Cyclosporine

Biologics

Others

The report has also provided a detailed breakup and analysis of the systemic lupus erythematosus (SLE) drugs market based on the drug class. This includes antimalarials drugs (chloroquine and hydroxycholroquine), non-steroidal anti-inflammatory drugs (NSAIDS), cytotoxic and immunosuppressive drugs (cyclophophamide, methotrexate, mycophenolate mofetil, tacrolimus, and cyclosporine), biologics, and others. According to the report, cytotoxic and immunosuppressive drugs represented the largest segment.

Mode of Delivery Insights:

Intravenous

Subcutaneous

Oral

A detailed breakup and analysis of the systemic lupus erythematosus (SLE) drugs market based on the mode of delivery has also been provided in the report. This includes intravenous, subcutaneous, and oral. According to the report, oral accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America was the largest market for systemic lupus erythematosus (SLE) drugs. Some of the factors driving the North America systemic lupus erythematosus (SLE) drugs market included easy access to healthcare, the rising awareness about the benefits of early diagnosis and treatment of SLE, and the easy availability of various generic drugs.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global systemic lupus erythematosus (SLE) drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AstraZeneca Plc, Aurinia Pharmaceuticals Inc., GSK plc, and ImmuPharma Plc.

Key Questions Answered in This Report

  • 1. How big is the global Systemic Lupus Erythematosus (SLE) drugs market?
  • 2. What is the expected growth rate of the global Systemic Lupus Erythematosus (SLE) drugs market during 2024-2032?
  • 3. What are the key factors driving the global Systemic Lupus Erythematosus (SLE) drugs market?
  • 4. What has been the impact of COVID-19 on the global Systemic Lupus Erythematosus (SLE) drugs market?
  • 5. What is the breakup of the global Systemic Lupus Erythematosus (SLE) drugs market based on the drug class?
  • 6. What is the breakup of the global Systemic Lupus Erythematosus (SLE) drugs market based on the mode of delivery?
  • 7. What are the key regions in the global Systemic Lupus Erythematosus (SLE) drugs market?
  • 8. Who are the key players/companies in the global Systemic Lupus Erythematosus (SLE) drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Systemic Lupus Erythematosus (SLE) Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Antimalarials Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Chloroquine
      • 6.1.2.2 Hydroxychloroquine
    • 6.1.3 Market Forecast
  • 6.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cytotoxic and Immunosuppressive Drugs
    • 6.3.1 Market Trends
    • 6.3.2 Key Segments
      • 6.3.2.1 Cyclophosphamide
      • 6.3.2.2 Methotrexate
      • 6.3.2.3 Mycophenolate Mofetil
      • 6.3.2.4 Tacrolimus
      • 6.3.2.5 Cyclosporine
    • 6.3.3 Market Forecast
  • 6.4 Biologics
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Mode of Delivery

  • 7.1 Intravenous
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Subcutaneous
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Oral
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 Drivers, Restraints, and Opportunities

  • 9.1 Overview
  • 9.2 Drivers
  • 9.3 Restraints
  • 9.4 Opportunities

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 AstraZeneca Plc
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Aurinia Pharmaceuticals Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
    • 13.3.3 GSK plc
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 ImmuPharma Plc
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Systemic Lupus Erythematosus Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Systemic Lupus Erythematosus Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 5: Global: Systemic Lupus Erythematosus Drugs Market: Breakup by Mode of Delivery (in %), 2023
  • Figure 6: Global: Systemic Lupus Erythematosus Drugs Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Systemic Lupus Erythematosus Drugs (Antimalarials Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Systemic Lupus Erythematosus Drugs (Antimalarials Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Systemic Lupus Erythematosus Drugs (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Systemic Lupus Erythematosus Drugs (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Systemic Lupus Erythematosus Drugs (Cytotoxic and Immunosuppressive Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Systemic Lupus Erythematosus Drugs (Cytotoxic and Immunosuppressive Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Systemic Lupus Erythematosus Drugs (Biologics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Systemic Lupus Erythematosus Drugs (Biologics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Systemic Lupus Erythematosus Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Systemic Lupus Erythematosus Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Systemic Lupus Erythematosus Drugs (Intravenous) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Systemic Lupus Erythematosus Drugs (Intravenous) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Systemic Lupus Erythematosus Drugs (Subcutaneous) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Systemic Lupus Erythematosus Drugs (Subcutaneous) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Systemic Lupus Erythematosus Drugs (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Systemic Lupus Erythematosus Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: North America: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: North America: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: United States: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: United States: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Canada: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Canada: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Asia-Pacific: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Asia-Pacific: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: China: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: China: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Japan: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Japan: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: India: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: India: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: South Korea: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: South Korea: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Australia: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Australia: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Indonesia: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Indonesia: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Others: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Others: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Europe: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Europe: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Germany: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Germany: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: France: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: France: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: United Kingdom: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: United Kingdom: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Italy: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Italy: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Spain: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Spain: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Russia: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Russia: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Others: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Others: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Latin America: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Latin America: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Brazil: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Brazil: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Mexico: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Mexico: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Others: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Others: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Middle East and Africa: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Middle East and Africa: Systemic Lupus Erythematosus Drugs Market: Breakup by Country (in %), 2023
  • Figure 71: Middle East and Africa: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Global: Systemic Lupus Erythematosus Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 73: Global: Systemic Lupus Erythematosus Drugs Industry: Value Chain Analysis
  • Figure 74: Global: Systemic Lupus Erythematosus Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Systemic Lupus Erythematosus Drugs Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Breakup by Mode of Delivery (in Million US$), 2024-2032
  • Table 4: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Systemic Lupus Erythematosus Drugs Market: Competitive Structure
  • Table 6: Global: Systemic Lupus Erythematosus Drugs Market: Key Players